Nutritional Supplementation with Panax Ginseng Extract and Bone Health in Osteoporotic Animal Models: A Systematic Review and Meta-Analysis

Why It Matters

The findings position Panax ginseng as a promising multi‑target alternative to conventional osteoporosis drugs, potentially addressing efficacy and safety gaps in current therapy.

Key Takeaways

• BMD increased with SMD 2.21 across 28 animal studies.
• Ginsenoside doses ≤40 mg/kg showed strongest bone benefits.
• Female and naturally aged models responded better than male or OVX models.
• Intraperitoneal delivery outperformed oral gavage in efficacy.
• Biomechanical strength and bone turnover markers improved without ALP change.

Pulse Analysis

Osteoporosis remains a global health crisis, with existing treatments such as bisphosphonates and denosumab hampered by safety concerns and poor adherence. In this context, the meta‑analysis of Panax ginseng extracts offers a comprehensive pre‑clinical evaluation, aggregating data from diverse animal models to demonstrate a robust increase in bone mineral density and structural integrity. By quantifying effect sizes across 28 studies, the review provides a level of statistical confidence rarely seen in isolated herbal research, making it a valuable reference for investors and biotech firms scouting novel bone‑health candidates.

The therapeutic promise of ginseng appears rooted in its ginsenoside constituents, which modulate key pathways like RANKL/OPG, Wnt/β‑catenin, and TGF‑β/Smad. Subgroup findings highlight a dose‑response ceiling at 40 mg/kg and a pronounced advantage for intraperitoneal administration, suggesting limited oral bioavailability that could be overcome with advanced delivery systems. Female and naturally aged models showed the strongest response, aligning with the herb’s weak estrogenic activity and its potential to counter age‑related bone loss. Importantly, the supplement boosted formation markers (PINP, osteocalcin) while suppressing resorption (TRACP), without altering alkaline phosphatase, indicating a unique decoupling of bone turnover processes.

Translating these pre‑clinical gains to humans will require standardized extracts, rigorous safety profiling, and formulation innovations such as nanocarriers or bone‑targeted particles to enhance systemic exposure. Ongoing gaps include limited blinding in animal trials and potential small‑study bias, underscoring the need for high‑quality, ARRIVE‑compliant research. Nevertheless, the aggregated evidence justifies early‑phase clinical exploration, particularly for post‑menopausal patients who cannot tolerate current pharmacotherapies. By addressing dosage, delivery, and mechanistic clarity, Panax ginseng could emerge as a cost‑effective, low‑toxicity adjunct or alternative in the osteoporosis treatment arsenal.